DNA Damage Repair in Brain Tumor Immunotherapy

Zhao, Shijun; Xu, Boya; Ma, Wenbin; Chen, Hao; Jiang, Chuanlu; Meng, Xiangqi

doi:10.3389/fimmu.2021.829268

Cited by 3 publications

(1 citation statement)

References 174 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike conventional tumor therapy, tumor immunotherapy is designed to recover the regular anti-tumor immune response by activating the tumor immune cycle for the detection and elimination of tumor cells. [4][5][6] Tumor immunotherapy is the fourth most common cancer treatment method after surgery, radiotherapy (RT) and chemotherapy. 7,8 Immunotherapy plays an essential part in the treatment of cancer by the activation or suppression of the immune system.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo¹,

Gao²,

Ahmed³

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo¹,

Gao²,

Ahmed³

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still’s Disease: A Single-Center Retrospective Observational Study

et al. 2022

View full text Add to dashboard Cite

Introduction The diagnosis of adult-onset Still’s disease (AOSD) is often delayed due to its clinical heterogeneity and lack of pathognomic features. Hence, there is an unmet need for an efficient diagnostic process. The major aim of this study was to compare the differences in disease outcomes between two groups of AOSD patients with and without implementation of the streamlined diagnostic process (SDP). Methods Of 172 febrile patients with skin rash and/or arthralgia, 112 individuals had AOSD. The tentative diagnosis of AOSD or non-AOSD was made with or without the SDP implementation. The selection criteria for AOSD outcomes analysis were as follows: (1) age at study entry older than 20 years, (2) fulfillment of the Yamaguchi criteria for AOSD diagnosis, and (3) a follow-up period longer than 6 months after initiation of therapy. Three outcome parameters were evaluated, including diagnosis lag period, the proportion of “early diagnosis,” and the proportion of achieving disease remission after a 6-month therapy. Results The SDP was implemented for expediting AOSD diagnosis in 41 (36%) enrolled patients (SDP-implemented group). The diagnosis lag period was significantly shorter in the SDP-implemented group (median 2.0 weeks, interquartile range [IQR] 1.0–2.5 weeks) than in the non-SDP-implemented group (4.0 weeks, IQR 2.0–6.0 weeks, p < 0.001). A significantly higher proportion of “early diagnosis” was also found in the SDP-implemented group (75.6%) compared with the non-SDP-implemented group (33.8%, p < 0.001). We revealed a significantly higher proportion of achieving remission in the SDP-implemented group (85.4%) compared with the non-SDP-implemented group (67.6%, p < 0.05). Logistic regression analysis revealed SDP implementation as a potential predictor of achieving disease remission. Conclusions Implementing an SDP for expediting diagnosis could improve outcomes for AOSD patients. This diagnostic process increased the early diagnosis rate and led to a higher disease remission rate. However, the beneficial effects of SDP implementation need further external validation.

show abstract

Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance

Vasilopoulos,

Güner,

Uça Apaydın

et al. 2023

Genes

View full text Add to dashboard Cite

Ionizing radiation can induce different types of DNA lesions, leading to genomic instability and ultimately cell death. Radiation therapy or radiotherapy, a major modality in cancer treatment, harnesses the genotoxic potential of radiation to target and destroy cancer cells. Nevertheless, cancer cells have the capacity to develop resistance to radiation treatment (radioresistance), which poses a major obstacle in the effective management of cancer. It has been shown that administration of platinum-based drugs to cancer patients can increase tumor radiosensitivity, but despite this, it is associated with severe adverse effects. Several lines of evidence support that activation of the DNA damage response and repair machinery in the irradiated cancer cells enhances radioresistance and cellular survival through the efficient repair of DNA lesions. Therefore, targeting of key DNA damage repair factors would render cancer cells vulnerable to the irradiation effects, increase cancer cell killing, and reduce the risk of side effects on healthy tissue. Herein, we have employed a computer-aided drug design approach for generating ab initio a chemical compound with drug-like properties potentially targeting two proteins implicated in multiple DNA repair pathways. The findings of this study could be taken into consideration in clinical decision-making in terms of co-administering radiation with DNA damage repair factor-based drugs.

show abstract

DNA Damage Repair in Brain Tumor Immunotherapy

Cited by 3 publications

References 174 publications

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still’s Disease: A Single-Center Retrospective Observational Study

Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance

Contact Info

Product

Resources

About